this effect may counteract the cardiovascular complications by the reduction of the systemic inflammation ( Figure 1 3.2 GLP1-RAs and AMPK GLP-1 (Glucagon-like peptide 1) is an incretin hormone, secreted from L-cells of the small intestine in a glucose-dependent manner, that enables stimulation of insulin secretion, increases pancreatic -cell mass, and inhibits glucagon secretion and gastric emptying, thereby reducing postprandial glycemia
D.VaskoV
As of now, theres no evidence suggesting that GLP-1 drugs interfere with these treatments
[DOI] [PubMed] [Google Scholar] 31.Fatima M.T., Islam Z., Ahmad E., Salahuddin P
Yuana Y, Sturk A, Nieuwland R
Wegovy is approved specifically for MASH with F2 to F3 fibrosis, not for general fatty liver